Delic Corp is best positioned to capture the full impact of the psychedelic wellness industry.

By Patricia Miller


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Delic Holdings Inc. is focused on bringing psychedelic wellness to the mainstream.

A health and wellness investment opportunity spanning multiple revenue streams.


Delic Holdings Inc is focused on bringing psychedelic wellness to the mainstream. It does this through an umbrella of related businesses it owns and operates to support scaling the impact and reach of treatment, including:

  1. trusted media and e-commerce platforms and in-person events to market the services directly to patients and consumers and gain data.

  2. a licensed lab to develop IP, R&D, and innovative high-quality and safe product lines.

  3. the largest and most accessible network of physical clinics to administer effective treatments.

Psychedelic wellness company Delic Holdings Inc is home to a growing array of consciousness-enhancing wellness assets.

With these tools in hand, the company is on a mission to better inform the public of all the good that can come from better understanding the hallucinogenic space.

For investors, this presents an exciting opportunity to invest in a promising growth story with real-world earning power.

Along with its research lab, website, blog, podcast, e-commerce store, and elaborate in-person events, Delic Corp is expanding to the largest chain of profitable treatment and wellness clinics in the world, while simultaneously conducting scientific research.

The future of hallucinogens will cater to a significant consumer packaged goods and products market — and its lab will allow it to serve that audience.

Delic Corp Labs develops IP and novel psychedelic products. It embraces licensing opportunities and works with other legal companies in biotech, and other progressive sectors, to develop increasingly effective products and treatments.

All of the above translates into money-spinning potential with a feel-good karmic quality.

Tackling mental health

Mental health problems have been rising in recent years, and Covid-19 has accelerated this trend.

21% of US adults now live with high levels of psychological distress. Unfortunately, younger generations are suffering the most, with 32% of these aged 18 to 29.

While conventional medicine has its place, it comes with an assortment of unwanted side effects.

Worse still, between 40% and 71% of patients taking antidepressants relapse.

The world is crying out for a viable solution, and this is where Delic Corp is poised to help.

A trusted chain of treatment clinics

Delic Corp is focused on bringing the most patients into a safe space and increasing accessibility to its clinics. With the close of a pending acquisition, it will operate the largest network of health clinics that currently offer ketamine treatment, which has shown great success with a number of significant mental health conditions. As future substances are FDA approved, it will provide those as well through its clinics.

It does not believe telehealth or remote health efforts to treat mental health conditions are as effective as personalized in-person clinical treatments with medical professionals.

Delic Corp also does not believe psychedelic treatment should be reserved for the elite or the wealthy. Its treatments are economical to ensure accessibility and the company works closely to help patients with insurance offset the total cost.

Early in July, Delic Holdings completed its acquisition of Ketamine Infusion Centers (KIC). It’s a tremendously exciting move for the group and one it can’t wait to expand.

The acquisition gives Delic Corp ownership of physical health clinics to complement its growing virtual and wellness center presence.

Further igniting its ambition to grow, Delic Corp intends to expand on a much grander scale. In fact, Delic Corp plans to operate the largest chain of ketamine clinics in the US.

This is fast emerging as a promising treatment for chronic diseases and prolonged pain. Moreover, clinical trials and peer-reviewed studies are showing positive results in their assessment of ketamine infusions.

As future treatments are legalized Delic Corp will offer additional options across its extensive provider network. No matter where you’re located in America, Delic Corp has a keen focus on serving multiple cities and the bulk of the population.

DISCOVER the multiple money-spinning opportunities locked up in this exciting stock! DOWNLOAD our Investor Deck TODAY!

What is this unique therapy?

Ketamine has an interesting history.

Back in the sixties, this numbing substance started out as an anesthetic for animals. It then evolved for human use in the seventies. Subsequently, the Vietnam war brought notoriety to the drug, as it helped treat soldiers for pain while keeping them calm.

Abuse of this drug in a party atmosphere is dangerous, but its use in therapy is an entirely different experience.

Nowadays, there are many happy tales of recovery from individuals previously on the brink of suicide, thanks to the anesthetic’s calming ability to heal.

Ketamine takes users into a dissociative experience, alternatively considered a ‘trip.’ This disassociation comes with visual and sensory illusions, euphoria, and a temporary bend in thought process.

It’s a revolutionary therapy helping people change for the better. And it works wonders in assisting individuals to break through a crisis.

With an epidemic of suicide occurring in society today, this unique therapy offers a viable solution in a safe and controlled setting.

Within 24 hours of treatment, ketamine has a 70% response rate. That is phenomenal, considering traditional antidepressants can take weeks to kick in, often with much lower response rates.

This is excellent news for investors because Delic Corp’s clinics sport high-profit margins, while this controlled substance is a proven effective treatment.

Saving lives, making money

Opening one of these clinics costs around $250k, but 25-30% operating profit means a break-even point within six months.

Treatments at Delic Corp’s clinics cost between $300 and $750 per session, with six-monthly booster sessions recommended. For many, these sessions are a gratifying experience they look forward to.

Better still, the treatments are far more affordable than alternative consciousness-enhancing therapies.

For instance, psilocybin treatments cost upwards of $10k a session, and MDMA sessions are projected to cost between $4k and $5k per session.

As the far cheaper option, this makes ketamine the ideal drug to implement at scale.

Delic Holdings Inc offers investors a unique way to profit from a life-changing solution to one of the world’s biggest health problems.

Building a wellness empire


The allure for investors is that Delic Corp intends to open and operate 26 clinics within the next 18 months.

Encouragingly, its clinics have been achieving revenues above $1.5 million since 2019.

Furthermore, Delic Corp’s expansion of the clincs will establish it as one of the largest of this type of clinical providers in the US.

Matt Stang, Founder and CEO of Delic Corp said:


Educate and empower

Delic Corp takes a unique approach by focusing on increasing accessibility to the most effective treatments for the most people. The company supports any efforts to bring these effective tools to the forefront of medical treatment and will work cooperatively across the industry to bring hallucinogenic wellness to the masses.

By also focusing on education Delic Corp can bring more people into the conversation about psychedelic solutions. Meanwhile, its battle-tested veterans will draw on lessons learned from the societal acceptance of cannabis through its early medical benefits.

Better still, Delic Corp provides another springboard from which it can educate those in need.

Delic Corp’s existing media platform and brand are well-received and admired. From its educational podium, Delic Corp can drive patients to its clinics, and from its clinics, can leverage its powerful bank of information.

This influential combination creates a full-circle entity, positioned to become a national market leader quickly.

While ketamine treatments are a primary division of Delic Corp’s business, its media empire educates on all aspects of psychedelic and alternative therapies.

Delic Corp’s extensive network also includes Delic Corps Labs, where its renowned scientists conduct licensed research into cannabis and psilocybin treatments.

Altogether Delic Corp is building a powerhouse in the mind-expanding realm. Armed with its accessible information, KIC chain, and Wellness Centers, it is empowering those suffering to escape from the clutches of devastating mind control.

Let the numbers do the talking

Meanwhile, Delic Corp is growing its audience across multiple media channels.

The company has created over 40 episodes of an educational and thought-provoking podcast to inform and discuss various psychedelic treatments.

Company co-founder and CCO Jackee Stang hosts each episode and has clocked up over 100k total streams. is Delic Corp’s unique digital magazine with over 5k original articles, 1.5m page views in 2020, and 800 first-page Google rankings.

Delic Corp is also harnessing the power of email with over 7k subscribers, 115k unique opens, and 11k clicks in 2020.

Finally, ‘Meet Delic’ has been discussed and featured on The Joe Rogan Experience, Daily Beast, Forbes, High Times, The Dr. Drew Podcast, and NBC News and is expected to draw thousands this November.

Shifting perception

Anxiety and depression are debilitating and extremely widespread. The rise of technology and the arrival of Covid-19 has exacerbated this, with people now suffering in droves.

These alternative treatments are finally gaining traction as a viable and organic solution in battling the world’s mental health problems.

Thankfully authorities are beginning to take notice. Although many of these types of substances were classified illegal decades ago, psilocybin therapy has recently been approved for clinical trials.

And breakthroughs in Ketamine, MDMA, and DMT treatments are all underway too.

The power of cognitive freedom cannot be overstated. It unlocks suppressed emotions, erases depressive thoughts, and allows the underlying personality to emerge triumphant.

Now Delic Corp can further leverage its educational ecosystem to an entirely new audience.

Discover why shroom stocks are an untapped industry crying out for investment! – READ our FREE Investor Deck

An educational transition

Education is critical in breaking the stigma surrounding psychedelics and embracing these wonder drugs at scale.

And this is something Delic Holdings Inc has mastered.

This journey from captivating the uninformed or anti-hallucinatory crowd, to ultimately changing opinion on a grand scale, is not as challenging as it may initially seem.

The cannabis sector has already succeeded in this regard and is well on its way to widespread legalization.

In many ways, this emerging space should have an easier road ahead because the cannabis journey has paved the way.

But more importantly, the potential for consciousness-enhancing treatments to solve major world health problems means it’s even more powerful in its scope.

Delic Corp is not simply making big claims with nothing to back them up.

It’s acting and capturing attention through its omni-channel approach. One of which is its real-world edutainment event in November.

Meet Delic, dubbed the world’s premiere psychedelic and wellness occasion, provides an opportunity to educate and inform. This much-anticipated event will bring together a mix of newcomers, businesses, and thought leaders.

With a business vision, Delic Corp is making money while conducting its journey of enlightenment.

Leveraging several income streams

At Delic Corp Labs, its team of scientists develops novel psychedelic compounds for legal mind-enhancing treatments.

This commercial wing of the business is exciting to investors because it’s been profitable since its founding.

And its lucrative customers include biotech, alcohol and tobacco, instrument manufacturers, and cannabis producers.

The fact that hallucinogenic treatments alone have the potential to treat so many individuals suffering is truly incredible.

Delic Corp is on a mission to educate those in need and change opinions along the way. All the while making money for shareholders through a variety of rewarding income streams.

Delic Corp. is an investment opportunity not to be missed.



This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Delic Holdings Inc. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of two hundred sixteen thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.

Explore more on these topics:



This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter